72 results
6-K
EX-99.1
ASLN
ASLAN Pharmaceuticals Ltd
22 Apr 24
Aslan Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab In Dupilumab-experienced Atopic Dermatitis Patients
8:29am
of the rescue medication for the purpose of efficacy analyses. Missing data were analysed using Last Observation Carried Forward imputation.
4.Least squares
424B5
ASLN
ASLAN Pharmaceuticals Ltd
12 Apr 24
Prospectus supplement for primary offering
8:15am
this offering to be used for any particular purpose, our management will have broad discretion as to the application of the net proceeds from … purpose. Pending application of the net proceeds as described above, we may initially invest the net proceeds in short-term, investment-grade
6-K
EX-99.1
ASLN
ASLAN Pharmaceuticals Ltd
12 Apr 24
Amendment No. 2 to the Open Market Sale Agreementsm
8:10am
correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon
S-8
ASLN
ASLAN Pharmaceuticals Ltd
12 Apr 24
Registration of securities for employees
6:37am
(the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering an additional 17,597,059 ordinary shares (an equivalent
F-3
griri 4a3ud10c7j89
25 Mar 24
Shelf registration (foreign)
4:46pm
424B5
aguom
14 Mar 24
Prospectus supplement for primary offering
6:24am
6-K
EX-4.1
am4 isrjbo6u
13 Mar 24
Aslan Pharmaceuticals Announces $5 Million Registered Direct Offering
7:27am
6-K
EX-10.1
9zqm fj4g
13 Mar 24
Aslan Pharmaceuticals Announces $5 Million Registered Direct Offering
7:27am
6-K
EX-99.1
9h1g27 yajvybhz7
24 Jan 24
Current report (foreign)
7:52am
6-K
EX-99.2
h3ee6lju
22 Dec 23
Current report (foreign)
4:24pm
F-6EF
uyzg883
26 Apr 23
Automatic registration for ADRs (foreign)
5:26pm
F-6EF
EX-99
1mnofmrn
26 Apr 23
Automatic registration for ADRs (foreign)
5:26pm
F-6EF
EX-99
s0mkpoeq
26 Apr 23
Automatic registration for ADRs (foreign)
5:26pm
6-K
EX-99.2
fh71v6 c3l34
21 Dec 22
Current report (foreign)
6:03am
6-K
EX-99.1
4brqtn1 rdkzr51r3ws
13 Sep 22
Amendment No. 1 to the Open Market Sale Agreementsm
4:31pm
424B5
dmun nrd8co7
13 Sep 22
Prospectus supplement for primary offering
4:05pm